Every lot published · search any lot number before you order

Retatrutide vs Tirzepatide vs Semaglutide: A Study-by-Study Guide

TRIUMPH-1, SURMOUNT-1 and STEP 1 are placebo-controlled studies of different interventions. Their published figures belong to their own populations, regimens, follow-up and analyses.

Retatrutide vs Tirzepatide vs Semaglutide: A Study-by-Study Guide. Three programs, different study questions. Population, Comparator, Outcome. GLP LIFE SCIENCES Ā· RESEARCH BRIEF 34 Three programs, different study questions Comparisons PopulationComparatorOutcome
Three programs, different study questions. Illustration for this research brief.

Three programs, different study questions

SURMOUNT-5 provides a direct comparison of tirzepatide and semaglutide, while TRIUMPH-5 is the registered direct retatrutide–tirzepatide comparison. These answer narrower questions than a three-drug ranking.

InterventionTrialFollow-upMean weight reductionContext
RetatrutideTRIUMPH-180 weeks28.3% vs 2.2% placeboSponsor efficacy analysis; 12 mg arm
TirzepatideSURMOUNT-172 weeks20.9% vs 3.1% placebo15 mg arm
SemaglutideSTEP 168 weeks14.9% vs 2.4% placebo2.4 mg arm
Separate placebo-controlled trials with different protocols.

These percentages come from separate trials. Their populations, study durations, analysis methods and placebo responses differ. In SURMOUNT-5, the direct tirzepatide and semaglutide comparison yielded 20.2% and 13.7% mean reductions, respectively, at 72 weeks.

How to interpret the evidence

A useful comparison puts each percentage next to its study name, population, follow-up and comparator.

Give the strongest weight to studies that randomized both treatments within a shared protocol for the clinical question you are asking.

Sources